Your browser doesn't support javascript.
Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine.
Li, Dapeng; Martinez, David R; Schäfer, Alexandra; Chen, Haiyan; Barr, Maggie; Sutherland, Laura L; Lee, Esther; Parks, Robert; Mielke, Dieter; Edwards, Whitney; Newman, Amanda; Bock, Kevin W; Minai, Mahnaz; Nagata, Bianca M; Gagne, Matthew; Douek, Daniel C; DeMarco, C Todd; Denny, Thomas N; Oguin, Thomas H; Brown, Alecia; Rountree, Wes; Wang, Yunfei; Mansouri, Katayoun; Edwards, Robert J; Ferrari, Guido; Sempowski, Gregory D; Eaton, Amanda; Tang, Juanjie; Cain, Derek W; Santra, Sampa; Pardi, Norbert; Weissman, Drew; Tomai, Mark A; Fox, Christopher B; Moore, Ian N; Andersen, Hanne; Lewis, Mark G; Golding, Hana; Seder, Robert; Khurana, Surender; Baric, Ralph S; Montefiori, David C; Saunders, Kevin O; Haynes, Barton F.
  • Li D; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Martinez DR; Department of Medicine, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Schäfer A; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Chen H; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Barr M; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Sutherland LL; Department of Medicine, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Lee E; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Parks R; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Mielke D; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Edwards W; Department of Medicine, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Newman A; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Bock KW; Department of Surgery, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Minai M; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Nagata BM; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Gagne M; Department of Medicine, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Douek DC; Infectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20814, USA.
  • DeMarco CT; Infectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20814, USA.
  • Denny TN; Infectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20814, USA.
  • Oguin TH; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20814, USA.
  • Brown A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20814, USA.
  • Rountree W; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Wang Y; Department of Medicine, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Mansouri K; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Edwards RJ; Department of Medicine, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Ferrari G; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Sempowski GD; Department of Medicine, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Eaton A; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Tang J; Department of Medicine, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Cain DW; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Santra S; Department of Medicine, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Pardi N; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Weissman D; Department of Medicine, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Tomai MA; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Fox CB; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Moore IN; Department of Medicine, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Andersen H; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Lewis MG; Department of Surgery, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Golding H; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Seder R; Department of Medicine, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Khurana S; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Baric RS; Department of Surgery, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Montefiori DC; Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, Silver Spring, MD, 20871, USA.
  • Saunders KO; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Haynes BF; Department of Medicine, Duke University School of Medicine, Durham, NC, 27710, USA.
Nat Commun ; 13(1): 6309, 2022 Oct 23.
Article in English | MEDLINE | ID: covidwho-2087203
ABSTRACT
Coronavirus vaccines that are highly effective against current and anticipated SARS-CoV-2 variants are needed to control COVID-19. We previously reported a receptor-binding domain (RBD)-sortase A-conjugated ferritin nanoparticle (scNP) vaccine that induced neutralizing antibodies against SARS-CoV-2 and pre-emergent sarbecoviruses and protected non-human primates (NHPs) from SARS-CoV-2 WA-1 infection. Here, we find the RBD-scNP induced neutralizing antibodies in NHPs against pseudoviruses of SARS-CoV and SARS-CoV-2 variants including 614G, Beta, Delta, Omicron BA.1, BA.2, BA.2.12.1, and BA.4/BA.5, and a designed variant with escape mutations, PMS20. Adjuvant studies demonstrate variant neutralization titers are highest with 3M-052-aqueous formulation (AF). Immunization twice with RBD-scNPs protect NHPs from SARS-CoV-2 WA-1, Beta, and Delta variant challenge, and protect mice from challenges of SARS-CoV-2 Beta variant and two other heterologous sarbecoviruses. These results demonstrate the ability of RBD-scNPs to induce broad neutralization of SARS-CoV-2 variants and to protect animals from multiple different SARS-related viruses. Such a vaccine could provide broad immunity to SARS-CoV-2 variants.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / Severe acute respiratory syndrome-related coronavirus / Nanoparticles / COVID-19 Topics: Vaccines / Variants Limits: Animals Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2022 Document Type: Article Affiliation country: S41467-022-33985-4

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / Severe acute respiratory syndrome-related coronavirus / Nanoparticles / COVID-19 Topics: Vaccines / Variants Limits: Animals Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2022 Document Type: Article Affiliation country: S41467-022-33985-4